Human medicines European public assessment report (EPAR): Celdoxome pegylated liposomal, doxorubicin hydrochloride, Date of authorisation: 15/09/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Entacapone Orion, entacapone, Date of authorisation: 18/08/2011, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Cegfila (previously Pegfilgrastim Mundipharma), pegfilgrastim, Date of authorisation: 19/12/2019, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Loqtorzi, Toripalimab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Anzupgo, Delgocitinib, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Eksunbi, ustekinumab, Date of authorisation: 12/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Aripiprazole Sandoz, aripiprazole, Date of authorisation: 20/08/2015, Revision: 11, Status: Authorised

Agenda of the HMPC meeting 23-25 September 2024

Committee for Herbal Medicinal Products (HMPC): 23-25 September 2024, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2024 to 25 September 2024